scispace - formally typeset
B

Barbara M. Torrisi

Researcher at Queen's University Belfast

Publications -  6
Citations -  623

Barbara M. Torrisi is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Transdermal & Stratum corneum. The author has an hindex of 6, co-authored 6 publications receiving 506 citations. Previous affiliations of Barbara M. Torrisi include Cardiff University.

Papers
More filters
Journal ArticleDOI

Microneedles for intradermal and transdermal drug delivery

TL;DR: Recent and future developments for MN technology including the latest type of MN design, challenges and strategies in MNs development as well as potential safety aspects based on comprehensive literature review pertaining to MN studies to date are focused on.
Journal ArticleDOI

Hydrogel-Forming Microneedle Arrays Allow Detection of Drugs and Glucose In Vivo: Potential for Use in Diagnosis and Therapeutic Drug Monitoring

TL;DR: Concentrations extracted from MN were clearly indicative of trends in blood in both rats and human volunteers, and strongly illustrates the potential of hydrogel-forming MN in minimally-invasive patient monitoring and diagnosis.
Journal ArticleDOI

Microneedle-mediated minimally invasive patient monitoring.

TL;DR: It is the view that microneedles will have an important role to play in clinical management of patients and will ultimately improve therapeutic outcomes for people worldwide.
Journal ArticleDOI

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin

TL;DR: This study is the first to characterise pocketed microneedle delivery of a liquid formulation into human skin and illustrates the potential of such systems for the cutaneous administration of potent proteins such as BT.
Journal ArticleDOI

Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.

TL;DR: It is aimed to highlight the utility of novel dissolving microneedle (MN)‐based delivery systems for enhanced transdermal protein delivery and the possibility of using minimally invasive MN technologies to replace conventional hypodermic vaccine injections.